- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02008435
Increasing the Effectiveness of the Diabetes Prevention Program
20. März 2018 aktualisiert von: Barbel Knauper, McGill University
Increasing the Effectiveness of the Diabetes Prevention Program Through If-then Plans and Mental Practice: A Parallel Randomized Trial
The Diabetes Prevention Program (DPP) is highly effective in promoting weight loss in overweight and obese individuals (e.g., 7% average loss of body weight), and thereby reducing the risk of developing weight-related health consequences.
One-on-one DPP sessions, however, are costly and the group-delivered DPP version, the Group Lifestyle Balance program (GLB), is less effective (4% average loss of body weight).
The aim of this two-arm parallel randomized controlled trial is to increase the effectiveness of the GLB by integrating habit formation techniques, namely if-then plans and their mental practice, into the program.
The study will provide evidence-based data on the effectiveness of an enhanced GLB intervention in promoting weight loss and in reducing weight-related risk factors for chronic health problems.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Please see brief summary.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
172
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Quebec
-
Montreal, Quebec, Kanada, H3A 1B1
- McGill University
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- men and women
- ages of 18 and 75
- overweight or obese (BMI 28-45 kg/m2)
- sedentary (< 200 min/week of moderate or vigorous exercise)
- waist circumference of >= 88cm for women and >= 102cm for men
Exclusion Criteria:
- diabetes (hemoglobin A1c < 7.0%).
- taking the medication metformin (used for treating pre-diabetes or diabetes)
- having been pregnant in the past 6 months or planning on becoming pregnant in the next 2 years
- currently undergoing treatment for cancer
- using medication that affects body weight (e.g., loop diuretics)
- being unable to participate in regular moderate physical activity
- having severe uncontrolled hypertension (> 190/100mm Hg)
- being unable to communicate in English or French
- being diagnosed with bulimia nervosa, currently active major depression, or other severe psychiatric disease (including dementia);
- suffering from a heart attack, stroke, or heart failure within the past 6 months
- experiencing excessive weight loss (more than 10 pounds or 4.54 kilograms) in the past 3 months
- currently participating in another weight loss program
- having had bariatric surgery in the past 2 years or plans on getting it in the near future
- planning on moving away from Montreal within the next year
- having another member of one's household enrolled in the program.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Enriched GLB
This arm aims to increase the effectiveness of the Group Lifestyle Balance (GLB) program by integrating habit formation techniques, namely if-then plans and their mental practice, into the program.
|
Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.
Andere Namen:
|
|
Aktiver Komparator: Standard GLB
This arm is the standard Group Lifestyle Balance (GLB) program, which is the group version of the Diabetes Prevention Program developed by the NIH.
|
This arm is the standard Group Lifestyle Balance program
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percent body weight loss
Zeitfenster: 3 months after beginning of the intervention
|
The primary outcome will be percent body weight loss from baseline to 3 months after the beginning of the intervention.
Weight in kg.
|
3 months after beginning of the intervention
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percent body weight loss
Zeitfenster: 12 months
|
Percent body weight loss 12 months after the beginning of the intervention.
Weight in kg.
|
12 months
|
|
Percent body weight loss
Zeitfenster: 24 months
|
Percent body weight loss 24 months after the beginning of the intervention.
Weight in kg.
|
24 months
|
|
Personal weight loss goal
Zeitfenster: 3 months
|
Reaching percent body weight loss goal (7% of body weight) from baseline to 3 months after the beginning of the intervention.
Weight in kg.
|
3 months
|
|
Personal weight loss goal
Zeitfenster: 12 months
|
Reaching percent body weight loss goal (7% of body weight) 12 months after the beginning of the intervention.
Weight in kg.
|
12 months
|
|
Personal weight loss goal
Zeitfenster: 24 months
|
Reaching percent body weight loss goal (7% of body weight) 24 months after the beginning of the intervention.
Weight in kg.
|
24 months
|
|
Personal exercise goal
Zeitfenster: 3 months
|
Reaching exercise goal (150 min/week) from baseline to 3 months after the beginning of the intervention.
Sum of minutes over 7 days.
|
3 months
|
|
Personal exercise goal
Zeitfenster: 12 months
|
Reaching exercise goal (150 min/week) 12 months after the beginning of the intervention.
Sum of minutes over 7 days.
|
12 months
|
|
Personal exercise goal
Zeitfenster: 24 months
|
Reaching exercise goal (150 min/week) 24 months after the beginning of the intervention.
Sum of minutes over 7 days.
|
24 months
|
|
Waist circumference
Zeitfenster: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
|
Waist circumference
Zeitfenster: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
|
Waist circumference
Zeitfenster: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
|
Hemoglobin A1c levels
Zeitfenster: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
|
Hemoglobin A1c levels
Zeitfenster: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
|
Hemoglobin A1c levels
Zeitfenster: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
|
Blood pressure
Zeitfenster: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
|
Blood pressure
Zeitfenster: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
|
Blood pressure
Zeitfenster: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
|
Total cholesterol/HDL ratio
Zeitfenster: 3 months
|
Risk factor for chronic health problems.
|
3 months
|
|
Total cholesterol/HDL ratio
Zeitfenster: 12 months
|
Risk factor for chronic health problems.
|
12 months
|
|
Total cholesterol/HDL ratio
Zeitfenster: 24 months
|
Risk factor for chronic health problems.
|
24 months
|
|
Physical activity duration
Zeitfenster: 3 months
|
Total minutes per week.
|
3 months
|
|
Physical activity duration
Zeitfenster: 12 months
|
Total minutes per week.
|
12 months
|
|
Physical activity duration
Zeitfenster: 24 months
|
Total minutes per week.
|
24 months
|
|
Number of steps taken per week
Zeitfenster: 3 months
|
Steps taken per week, recorded using a pedometer.
|
3 months
|
|
Number of steps taken per week
Zeitfenster: 12 months
|
Steps taken per week, recorded using a pedometer.
|
12 months
|
|
Number of steps taken per week
Zeitfenster: 24 months
|
Steps taken per week, recorded using a pedometer.
|
24 months
|
|
Exercise stress test (EST)
Zeitfenster: 3 months
|
3 months
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Self-Report Index of Habit Strength
Zeitfenster: 3 months
|
Self-monitoring and behaviors
|
3 months
|
|
Self-Report Index of Habit Strength
Zeitfenster: 12 months
|
Self-monitoring and behaviors
|
12 months
|
|
Self-Report Index of Habit Strength
Zeitfenster: 24 months
|
Self-monitoring and behaviors
|
24 months
|
|
Habit formation indices of weight tracking
Zeitfenster: 3 months
|
Frequency of weight tracking.
|
3 months
|
|
Habit formation indices of weight tracking
Zeitfenster: 12 months
|
Frequency of weight tracking.
|
12 months
|
|
Habit formation indices of weight tracking
Zeitfenster: 24 months
|
Frequency of weight tracking.
|
24 months
|
|
Habit formation indices of physical activity tracking
Zeitfenster: 3 months
|
Frequency of physical activity tracking.
|
3 months
|
|
Habit formation indices of physical activity tracking
Zeitfenster: 12 months
|
Frequency of physical activity tracking.
|
12 months
|
|
Habit formation indices of physical activity tracking
Zeitfenster: 24 months
|
Frequency of physical activity tracking.
|
24 months
|
|
Habit formation indices of fat grams and calorie tracking
Zeitfenster: 3 months
|
Frequency of food tracking.
|
3 months
|
|
Habit formation indices of fat grams and calorie tracking
Zeitfenster: 12 months
|
Frequency of food tracking.
|
12 months
|
|
Habit formation indices of fat grams and calorie tracking
Zeitfenster: 24 months
|
Frequency of food tracking.
|
24 months
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Studienleiter: Ilka Lowensteyn, PhD, McGill University
- Studienleiter: Lawrence Joseph, PhD, McGill University
- Studienleiter: Aleksandra Luszczynska, PhD, University of Colorado, Denver
- Studienleiter: Steven Grover, MD, McGill University
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Allgemeine Veröffentlichungen
- Knauper B, Shireen H, Carriere K, Frayn M, Ivanova E, Xu Z, Lowensteyn I, Sadikaj G, Luszczynska A, Grover S; McGill CHIP Healthy Weight Program Investigators. The effects of if-then plans on weight loss: results of the 24-month follow-up of the McGill CHIP Healthy Weight Program randomized controlled trial. Trials. 2020 Jan 7;21(1):40. doi: 10.1186/s13063-019-4014-z.
- Knauper B, Carriere K, Frayn M, Ivanova E, Xu Z, Ames-Bull A, Islam F, Lowensteyn I, Sadikaj G, Luszczynska A, Grover S; McGill CHIP Healthy Weight Program Investigators. The Effects of If-Then Plans on Weight Loss: Results of the McGill CHIP Healthy Weight Program Randomized Controlled Trial. Obesity (Silver Spring). 2018 Aug;26(8):1285-1295. doi: 10.1002/oby.22226. Epub 2018 Jun 28.
- Knauper B, Ivanova E, Xu Z, Chamandy M, Lowensteyn I, Joseph L, Luszczynska A, Grover S. Increasing the effectiveness of the Diabetes Prevention Program through if-then plans: study protocol for the randomized controlled trial of the McGill CHIP Healthy Weight Program. BMC Public Health. 2014 May 18;14:470. doi: 10.1186/1471-2458-14-470.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
1. April 2013
Primärer Abschluss (Tatsächlich)
1. Dezember 2017
Studienabschluss (Tatsächlich)
1. Dezember 2017
Studienanmeldedaten
Zuerst eingereicht
6. Dezember 2013
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
6. Dezember 2013
Zuerst gepostet (Schätzen)
11. Dezember 2013
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
21. März 2018
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
20. März 2018
Zuletzt verifiziert
1. März 2018
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- MOP-123242
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Enriched GLB
-
Hangzhou GluBio Pharmaceutical Co., Ltd.RekrutierungNon-Hodgkin-LymphomChina
-
GluBio Therapeutics Inc.RekrutierungAkute myeloische Leukämie | Myelodysplastische SyndromeVereinigte Staaten
-
University of PittsburghUnited States Department of DefenseAbgeschlossenMetabolisches Syndrom | PrädiabetesVereinigte Staaten
-
University of PittsburghAbgeschlossenLebensqualität | Fettleibigkeit | Physische Aktivität | Ernährungsumstellung | Herz-Kreislauf-Risikofaktor | Mobilitätseinschränkung | Essverhalten
-
Ohio State UniversityAbgeschlossen
-
Hangzhou GluBio Pharmaceutical Co., Ltd.RekrutierungAkute myeloische Leukämie | Myelodysplastische Syndrome | Polycythaemia Vera | Essentielle Thrombozythämie | Myelofibrose | Myeloische MalignitätChina
-
Lovoria WilliamsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Aktiv, nicht rekrutierend
-
University of PittsburghRobert C. Atkins FoundationAbgeschlossenDiabetesVereinigte Staaten
-
Baylor Research InstituteAbgeschlossenFettleibigkeit | Gewichtsverlust | Ernährungsumstellung | Verletzungen des RückenmarksVereinigte Staaten
-
Tulane UniversityUniversity of Pennsylvania; National Heart, Lung, and Blood Institute (NHLBI); Pennington Biomedical Research CenterRekrutierungHyperglykämie | Fettleibigkeit | Prädiabetes | Schwangerschaftsdiabetes | Glukoseintoleranz während der Schwangerschaft | Lebensstil, gesundVereinigte Staaten